Emergent Biosolutions

Emergent Biosolutions is a global specialty biopharmaceutical company offering specialized products that address medical needs and emerging health threats. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. Emergent Biosolutions focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats. 

Company Growth (employees)
Gaithersburg, US
Size (employees)
1,098 (est)
Emergent Biosolutions was founded in 1998 and is headquartered in Gaithersburg, US

Emergent Biosolutions Office Locations

Emergent Biosolutions has offices in Gaithersburg, Washington, Lansing, Winnipeg and in 6 other locations
Gaithersburg, US (HQ)
400 400 Professional Dr
Baltimore, US
5901 E Lombard St
Hattiesburg, US
46 Shelby Thames Dr
Lansing, US
3500 N Martin Luther King Jr Blvd
Washington, US
1225 1455 Pennsylvania Ave NW
Winnipeg, CA
155 Innovation Dr
Show all (11)

Emergent Biosolutions Financials and Metrics

Emergent Biosolutions Financials

Emergent Biosolutions's revenue was reported to be $488.8 m in FY, 2016

Revenue (Q3, 2017)

149.4 m

Net income (Q3, 2017)

33.6 m

EBIT (Q3, 2017)

47.8 m

Market capitalization (16-Feb-2018)

2.5 b

Cash (30-Sep-2017)

341 m
Emergent Biosolutions's current market capitalization is $2.5 b.
USDFY, 2014FY, 2015FY, 2016


404.5 m489.3 m488.8 m

Revenue growth, %


R&D expense

108.3 m

General and administrative expense

143.7 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


89.1 m53.9 m110.3 m138 m63.6 m126.1 m164.9 m111 m101.5 m142.9 m116.9 m100.8 m149.4 m

Cost of goods sold

20.1 m

Gross profit

69 m

Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016


280.5 m312.8 m271.5 m

Accounts Receivable

58.8 m120.8 m138.5 m


65.7 m76.9 m74 m

Current Assets

432.2 m538.6 m510.2 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


214.8 m308.7 m341 m333.4 m298.9 m270.2 m315.6 m341 m

Accounts Receivable

99.7 m57 m69.6 m66.7 m69.6 m128.1 m102.5 m129.4 m


84.7 m80.1 m88.2 m96.7 m81.2 m70.7 m70.5 m68.9 m

Current Assets

435.5 m473.5 m528.2 m528 m480 m489.2 m509.7 m556 m
USDFY, 2014FY, 2015FY, 2016

Net Income

36.7 m62.9 m51.8 m

Accounts Receivable

21.4 m(64 m)(22.4 m)


4.2 m(11.3 m)(9 m)

Accounts Payable

(9.3 m)4.7 m(14.8 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

15 m(20.2 m)(15.2 m)6.6 m(21.5 m)(7.4 m)29.5 m4 m(7 m)14.4 m10.5 m15.1 m48.7 m

Depreciation and Amortization

13.5 m6.8 m15.3 m24.3 m8.5 m17.3 m25.9 m8.8 m17.8 m28.2 m10.2 m20.1 m29.9 m

Accounts Receivable

66 m17.6 m2.3 m36.1 m(5.2 m)(40.9 m)1.7 m51.2 m53.9 m45 m10.6 m36.2 m9.4 m


(1.2 m)(4 m)1.2 m4.7 m(16.5 m)(19 m)(14.4 m)(11.3 m)(19.7 m)(16.2 m)3.3 m3.5 m5.1 m
USDY, 2017


136.1 k

Financial Leverage

1.5 x
Show all financial metrics

Emergent Biosolutions Market Value History

Emergent Biosolutions's Web-traffic and Trends

Emergent Biosolutions Online and Social Media Presence

Emergent Biosolutions Company Life and Culture

You may also be interested in